Roxadustat
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Kidney Disease
Conditions
Chronic Kidney Disease, Renal Anemia
Trial Timeline
Jan 16, 2024 → Oct 30, 2027
NCT ID
NCT05970172About Roxadustat
Roxadustat is a phase 3 stage product being developed by Astellas Pharma for Chronic Kidney Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05970172. Target conditions include Chronic Kidney Disease, Renal Anemia.
What happened to similar drugs?
20 of 20 similar drugs in Chronic Kidney Disease were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05970172 | Phase 3 | Recruiting |
| NCT04408820 | Pre-clinical | Completed |
| NCT04076943 | Phase 2 | Completed |
| NCT03960489 | Phase 1 | Completed |
| NCT02964936 | Phase 3 | Completed |
| NCT02965040 | Phase 1 | Completed |
| NCT02780726 | Phase 3 | Completed |
| NCT02780141 | Phase 3 | Completed |
| NCT02779764 | Phase 3 | Completed |
| NCT01630889 | Phase 2 | Completed |
| NCT01244763 | Phase 2 | Completed |
| NCT01083888 | Phase 1 | Completed |
Competing Products
20 competing products in Chronic Kidney Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Levofloxacin 500 | Dr. Reddy's Laboratories | Pre-clinical | 23 |
| mRNA-0184 | Moderna | Phase 1 | 0 |
| Lubiprostone + Lubiprostone + Placebo | Dr. Reddy's Laboratories | Phase 3 | 37 |
| macitentan 10 mg | BML, Inc. | Phase 3 | 32 |
| KPL-716 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 29 |
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 36 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | 23 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 35 |
| THB001 | Third Harmonic Bio | Phase 1 | 11 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 26 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 14 |
| Briquilimab | Jasper Therapeutics | Phase 2 | 29 |
| Empagliflozin + Matching placebo | Eli Lilly | Phase 3 | 40 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 29 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | 44 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 35 |
| Pirtobrutinib | Eli Lilly | Phase 2 | 42 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | 21 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | 27 |
| LYR-210 | Lyra Therapeutics | Phase 2 | 25 |